Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study

Jane C. Figueiredo, Robert W. Haile, Leslie Bernstein, Kathleen E. Malone, Joan Largent, Bryan Langholz, Charles F. Lynch, Lisbeth Bertelsen, Marinela Capanu, Patrick Concannon, Åke Borg, Anne-Lise Borresen-Dale, Anh Diep, Sharon Teraoka, Therese Törngren, Shanyan Xue, Jonine L. Bernstein

Research output: Contribution to journalArticlepeer-review

23 Citations (SciVal)

Abstract

The potential effects of oral contraceptive (OC) and postmenopausal hormone (PMH) use are not well understood among BRCA1 or BRCA2 (BRCA1/2) deleterious mutation carriers with a history of breast cancer. We investigated the association between OC and PMH use and risk of contralateral breast cancer (CBC) in the WECARE (Women's Environment, Cancer, and Radiation Epidemiology) Study. The WECARE Study is a population-based case-control study of 705 women with asynchronous CBC and 1,398 women with unilateral breast cancer, including 181 BRCA1/2 mutation carriers. Risk-factor information was assessed by telephone interview. Mutation status was measured using denaturing high-performance liquid chromatography followed by direct sequencing in all participants. Outcomes, treatment, and tumor characteristics were abstracted from medical records. Ever use of OCs was not associated with risk among noncarriers (RR = 0.87; 95% CI = 0.66-1.15) or BRCA2 carriers (RR = 0.82; 95% CI = 0.21-3.13). BRCA1 carriers who used OCs had a nonsignificant greater risk than nonusers (RR = 2.38; 95% CI = 0.72-7.83). Total duration of OC use and at least 5 years of use before age 30 were associated with a nonsignificant increased risk among mutation carriers but not among noncarriers. Few women had ever used PMH and we found no significant associations between lifetime use and CBC risk among carriers and noncarriers. In conclusion, the association between OC/PMH use and risk of CBC does not differ significantly between carriers and noncarriers; however, because carriers have a higher baseline risk of second primaries, even a potential small increase in risk as a result of OC use may be clinically relevant.
Original languageEnglish
Pages (from-to)175-183
JournalBreast Cancer Research and Treatment
Volume120
Issue number1
DOIs
Publication statusPublished - 2010

Subject classification (UKÄ)

  • Cancer and Oncology

Keywords

  • BRCA2
  • BRCA1
  • Postmenopausal hormones
  • contraceptives
  • Oral
  • Contralateral
  • Breast cancer
  • Asynchronous bilateral

Fingerprint

Dive into the research topics of 'Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study'. Together they form a unique fingerprint.

Cite this